Xenetic Biosciences, Inc. (XBIO)
| Market Cap | 5.81M |
| Revenue (ttm) | 2.52M |
| Net Income (ttm) | -4.70M |
| Shares Out | 1.54M |
| EPS (ttm) | -3.06 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,797 |
| Open | 3.670 |
| Previous Close | 3.700 |
| Day's Range | 3.670 - 3.808 |
| 52-Week Range | 2.780 - 5.200 |
| Beta | 2.26 |
| Analysts | Hold |
| Price Target | n/a |
| Earnings Date | Nov 8, 2024 |
About XBIO
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies for hard to treat cancers. The company’s proprietary DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments that targets pancreatic cancer comprising pancreatic ductal adenocarcinoma, colorectal carcinoma, and other gastrointestinal cancer. Its product pipeline in... [Read more]
Financial Performance
In 2023, Xenetic Biosciences's revenue was $2.54 million, an increase of 48.80% compared to the previous year's $1.71 million. Losses were -$4.13 million, -36.90% less than in 2022.
Financial StatementsNews
Xenetic Biosciences, Inc. Enters into Materials Transfer Agreement with Tokyo Medical University for the Advancement of Its DNase-Based Oncology Platform
Xenetic to supply recombinant DNase I to Tokyo Medical University for evaluation as a treatment of Ewing sarcoma in unique preclinical model FRAMINGHAM, MA / ACCESSWIRE / October 17, 2024 / Xenetic Bi...
Xenetic Biosciences, Inc. Presents at the H.C. Wainwright 26th Annual Global Investment Conference
FRAMINGHAM, MA / ACCESSWIRE / September 11, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology tec...
Xenetic Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update
Ongoing preclinical studies with data expected before year end Focus on demonstration of DNase-based oncology program in clinical proof-of-concept studies in multiple indications Ended the quarter wit...
Xenetic Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
Ongoing preclinical studies with multiple data readouts expected throughout remainder of 2024 Continued advancement of DNase-based oncology program towards Phase 1 clinical study for the treatment of ...
Xenetic Biosciences, Inc. Reports Full Year 2023 Financial Results
Continued advancement of DNase-based oncology program towards Phase 1 clinical study for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors Ended the year with...
Xenetic Biosciences, Inc. Enters into Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform
- Company building growing body of preclinical data to guide pathway to first in human trial for DNase-based oncology platform FRAMINGHAM, MA / ACCESSWIRE / January 17, 2024 / Xenetic Biosciences, Inc...
Xenetic Biosciences, Inc. Reports Third Quarter 2023 Financial Results
Encouraging growing body of preclinical data guiding pathway to first in human trial for DNase-based oncology platform Driving development towards Phase 1 program for the treatment of pancreatic carci...
Xenetic Biosciences, Inc. to Participate at the Virtual Investor Ask the CEO Conference
Live moderated webcast with Jeffrey Eisenberg, Chief Executive Officer of Xenetic Biosciences on Tuesday, October 24th at 1:00 PM ET FRAMINGHAM, MA / ACCESSWIRE / October 11, 2023 / Xenetic Bioscience...
Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 25th Annual Global Investment Conference
FRAMINGHAM, MA / ACCESSWIRE / September 5, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology tech...
Xenetic Biosciences, Inc. Reports Second Quarter 2023 Financial Results
- Company continues to execute on plan to advance DNase-based oncology program towards Phase 1 clinical development for the treatment of pancreatic carcinoma and other locally advanced or metastatic s...
Xenetic Biosciences, Inc. to Participate in the Virtual Investor Summer Spotlight Series
Live moderated video webcast on Wednesday, July 12th at 10:00 AM ET FRAMINGHAM, MA / ACCESSWIRE / July 5, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutic...
Xenetic Biosciences, Inc. Announces Reverse Stock Split of Common Stock
FRAMINGHAM, MA / ACCESSWIRE / May 12, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technolog...
Xenetic Biosciences, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update
- Continued progress with the DNase-based oncology program towards Phase 1 study for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors - Ended the quarter wit...
Xenetic Biosciences, Inc. Bolsters R&D and Regulatory Expertise with Appointment of Reid P. Bissonnette, Ph.D.
Dr. Bissonnette brings over 25 years in small molecule and biotherapeutic drug discovery and development, oncology and inflammation research and regulatory expertise FRAMINGHAM, MA / ACCESSWIRE / May ...
Xenetic Biosciences, Inc. Adds Business Development Expertise with Appointment of Scott N. Cullison
Mr. Cullison brings over 20 years of experience in the pharmaceutical industry with a broad range of expertise across business development and strategic planning FRAMINGHAM, MA / ACCESSWIRE / May 3, 2...
Xenetic Biosciences, Inc. Announces Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform
- Collaboration provides a significant step forward in the advancement of Xenetic's DNase-based oncology program towards Phase 1 clinical development - Systemic DNase program initially targeting multi...
Xenetic Biosciences, Inc. Reports Full Year 2022 Financial Results and Provides Business Update
- Year marked by transformational strategic license of the DNase oncology platform and shift in focus to treatment of locally advanced or metastatic solid tumors - DNase program progressing towards Ph...
JTC Team to Host Virtual Investor NETs in Cancer Spotlight Event Featuring Xenetic Biosciences
- Live moderated video webcast with members of the Xenetic leadership team and recognized oncology leader and NETs researcher, Jonathan Spicer, MD, PhD on Wednesday, March 29th at 11:00 AM ET - FRENCH...
Xenetic Biosciences, Inc. to Present at the Virtual Investor NETs in Cancer Spotlight Event
Live video webcast with moderated roundtable with members of the Xenetic leadership team and recognized oncology leader and NETs researcher, Jonathan Spicer, MD, PhD on Wednesday, March 29th at 11:00 ...
Xenetic Biosciences, Inc. Announces Notice of Allowance for Canadian Patent Covering Use of DNase Enzyme for Preventing or Ameliorating Toxicity Associated with Chemotherapy
FRAMINGHAM, MA / ACCESSWIRE / January 17, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology techn...
Xenetic Biosciences, Inc. to Present at the Virtual Investor 2023 Companies to Watch Event
Live video webcast on Tuesday, January 17th at 10:00 AM ET FRAMINGHAM, MA / ACCESSWIRE / January 5, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical com...
Xenetic Biosciences, Inc. Engages Leading NETs Research Expert, Jonathan Spicer, MD, PhD for Advancement of DNase Oncology Platform
Appointment of Dr. Spicer to Scientific Advisory Board bolsters expertise in Neutrophil Extracellular Traps ("NETs") in cancer biology and provides valuable assistance in advancing development of the ...
Xenetic Biosciences, Inc. Reports Third Quarter 2022 Financial Results and Provides Business Update
- Continued advancement of lead technology, DNase-based oncology platform, in locally advanced or metastatic solid tumors towards Phase 1 clinical development - Ended the quarter with $13.8 million of...
Xenetic Biosciences, Inc. Announces Signing of Patent Assignment Related to Collaboration With VolitionRx Limited and CLS Therapeutics
Signing of patent assignment from CLS Therapeutics as part of a collaboration agreement with Volition and CLS Therapeutics to develop NETs-targeted adoptive cell therapies for the treatment of cancer ...
Xenetic Biosciences, Inc. Appoints Globally Recognized Oncology Leader, Allan Tsung, MD to its Scientific Advisory Board
FRAMINGHAM, MA / ACCESSWIRE / October 4, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology techno...